McAdam LLC’s GSK GSK Stock Holding History

McAdam LLC’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-225	Closed	-$11K	–	267
2018 Q3	$11K	Buy	225 +2	+0.9%	+$102	﹤0.01%	325
2018 Q2	$11K	Sell	223 -98	-31%	-$4.94K	﹤0.01%	318
2018 Q1	$16K	Buy	+321	New	+$14.9K	0.01%	275

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.86B AUM 15.33% 1-Year Est. Return

McAdam LLC's GSK Position: Q4 2018 in Review

McAdam LLC sold out of GSK (GSK) in Q4 2018, closing a stake of 225 shares — an estimated $11K sold.

McAdam LLC first reported a position in GSK in Q1 2018 and held it in 3 quarters. The position peaked at $16K in Q1 2018. 799 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

McAdam LLC reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
McAdam LLC sold 225 GSK shares in Q4 2018, an estimated $11K.
McAdam LLC first reported a position in GSK in Q1 2018 and held it in 3 quarters.
McAdam LLC's GSK position peaked at $16K in Q1 2018.
799 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on McAdam LLC's 13F filing for Q4 2018, filed 30 Jan 2019.